D. Boral Capital Reiterates “Buy” Rating for Plus Therapeutics (NASDAQ:PSTV)

D. Boral Capital reissued their buy rating on shares of Plus Therapeutics (NASDAQ:PSTV) in a research report report published on Friday morning,Benzinga reports. The firm currently has a $9.00 target price on the stock.

PSTV has been the subject of several other reports. HC Wainwright lowered their price objective on shares of Plus Therapeutics from $8.00 to $5.50 and set a “buy” rating for the company in a research note on Friday. Ascendiant Capital Markets lowered their price target on Plus Therapeutics from $20.00 to $19.00 and set a “buy” rating for the company in a research report on Monday, December 9th.

Plus Therapeutics Trading Down 23.7 %

Shares of NASDAQ:PSTV opened at $1.16 on Friday. The firm has a market cap of $6.84 million, a price-to-earnings ratio of -0.46 and a beta of 0.73. The stock’s 50-day moving average price is $1.11 and its two-hundred day moving average price is $1.24. Plus Therapeutics has a 12-month low of $0.24 and a 12-month high of $2.67.

Plus Therapeutics (NASDAQ:PSTV) last released its earnings results on Thursday, March 27th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.16). The company had revenue of $1.80 million for the quarter, compared to analyst estimates of $1.19 million. As a group, research analysts forecast that Plus Therapeutics will post -2.3 earnings per share for the current fiscal year.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.